In Q4 2025, Bristol-Myers Squibb delivered solid revenue growth driven by its Growth Portfolio, while GAAP earnings were impacted by acquired IPR&D charges, offset by strong non-GAAP profitability.

Bristol Myers Squibb delivered solid Q3 2025 results with strong growth in its new product portfolio and improved revenue, EPS, and net income. Legacy products declined but were offset by rising contributions from Breyanzi, Camzyos, and Reblozyl.

Bristol Myers Squibb delivered $12.3B in revenue for Q2 2025, with strength in its Growth Portfolio offset by legacy product declines. GAAP EPS dropped to $0.64 and net income declined due to a $1.5B IPRD charge related to a new partnership with BioNTech.

Bristol Myers Squibb posted a revenue decline but achieved strong profitability in Q1 2025, with a significant rebound in net income and EPS driven by the growth portfolio and cost control measures.

Bristol Myers Squibb reported Q4 2024 revenues of $12.3 billion, an 8% increase year-over-year, driven by the Growth Portfolio and higher demand for Eliquis. GAAP EPS was $0.04, and Non-GAAP EPS was $1.67. The company is expanding its strategic productivity initiative to deliver ~$2 billion in additional cost savings by the end of 2027 and provides 2025 guidance with revenues of ~$45.5 billion and Non-GAAP EPS range of $6.55 to $6.85.

Bristol Myers Squibb reported strong third-quarter results, driven by the Growth Portfolio and Eliquis, with revenues increasing by 8% to $11.9 billion. The company achieved U.S. approval of Cobenfy and is raising its 2024 revenue and Non-GAAP EPS guidance.

Bristol Myers Squibb reported second quarter revenues of $12.2 billion, a 9% increase (+11% adjusting for foreign exchange). The Growth Portfolio revenues were $5.6 billion, increasing 18% (+21% adjusting for foreign exchange). GAAP EPS was $0.83 and Non-GAAP EPS was $2.07.

Bristol Myers Squibb's first quarter revenues reached $11.9 billion, a 5% increase (6% adjusting for foreign exchange). The company completed several strategic transactions, including the acquisitions of Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, and a collaboration with SystImmune. GAAP loss per share was $(5.89), while non-GAAP loss per share was $(4.40), impacted by acquired IPRD charges and licensing income.

Bristol Myers Squibb reported Q4 2023 revenues of $11.5 billion, a 1% increase year-over-year. GAAP EPS was $0.87, while non-GAAP EPS reached $1.70. The company's in-line and new product portfolio saw a 9% revenue increase, reaching $9.8 billion. Strategic acquisitions and collaborations, including Karuna Therapeutics, RayzeBio, and SystImmune, were announced to bolster long-term growth.

Bristol Myers Squibb reported third-quarter revenues of $11.0 billion, a decrease of 2% compared to the same period last year. The decline was primarily due to lower sales of Revlimid, which was partially offset by growth in the new product portfolio and in-line products. The company reported GAAP earnings per share of $0.93 and non-GAAP EPS of $2.00.

Bristol Myers Squibb reported second-quarter revenues of $11.2 billion, a 6% decrease year-over-year, primarily due to a rapid decline in Revlimid sales. The company is revising its full-year financial guidance due to this decline but reaffirms its 2020-2025 financial targets and announces a $4 billion accelerated share repurchase agreement.

Bristol-Myers Squibb reported first-quarter revenues of $11.3 billion, a decrease of 3% compared to the previous year, but saw an 8% increase in revenue from in-line products and the new product portfolio. GAAP EPS was $1.07, and non-GAAP EPS was $2.05. The company is adjusting its GAAP EPS guidance for 2023 while affirming its non-GAAP financial guidance.

Bristol Myers Squibb reported a decrease in fourth-quarter revenues by 5% to $11.4 billion, driven by recent LOE products and foreign exchange impacts, which was partially offset by in-line products and new product portfolio. The company reported GAAP EPS of $0.95 and non-GAAP EPS of $1.82 for the quarter.

Bristol Myers Squibb reported third quarter revenues of $11.2 billion, a decrease of 3% compared to the same period in 2021. The company's in-line and new product portfolio revenues increased 8% to $8.6 billion. Earnings per share were $0.75, and non-GAAP EPS was $1.99.

Bristol Myers Squibb reported Q2 2022 financial results, showing revenue of $11.9 billion, a 2% increase year-over-year, or 5% when adjusted for foreign exchange. The company posted GAAP EPS of $0.66 and non-GAAP EPS of $1.93. Revenue growth was driven by in-line products and new product portfolio, but was partially offset by recent LOE products and foreign exchange impacts.

Bristol Myers Squibb reported first quarter revenues of $11.6 billion, a 5% increase year-over-year, driven by in-line products and the new product portfolio. GAAP EPS was $0.59 and non-GAAP EPS was $1.96. The company also advanced its product pipeline with FDA approvals for Opdualag and Camzyos.

Bristol Myers Squibb reported Q4 2021 revenues of $12.0 billion, an increase of 8%, driven by Eliquis, Immuno-Oncology and new product portfolios. The company posted earnings per share of $1.07 and non-GAAP EPS of $1.83.

Bristol Myers Squibb reported a strong third quarter in 2021, marked by a 10% increase in revenues to $11.6 billion. The company saw GAAP EPS of $0.69 and non-GAAP EPS of $2.00. Advances in the product pipeline included FDA Priority Review for relatlimab and nivolumab combination.

Bristol Myers Squibb reported strong second-quarter results with revenues of $11.7 billion, a 16% increase year-over-year. The company achieved significant regulatory and clinical milestones, and delivered strong commercial performance, including Opdivo's return to growth.

Bristol Myers Squibb reported solid growth in the first quarter of 2021, driven by continued sales growth and advancement of the company's product pipeline. The company posted revenues of $11.1 billion, an increase of 3% year-over-year, and GAAP earnings per share of $0.89 and non-GAAP EPS of $1.74. The company also strengthened its leadership in Immuno-Oncology and advanced its Cell Therapy Franchise.

Bristol Myers Squibb reported Q4 2020 revenues of $11.1 billion, a 39% increase, and a GAAP loss per share of $4.45, with non-GAAP EPS of $1.46. The company completed the acquisition of MyoKardia and announced a debt tender offer. They also delivered positive results from a trial evaluating Deucravacritinib for plaque psoriasis and announced a licensing agreement with The Rockefeller University for a COVID-19 treatment.

Bristol Myers Squibb reported a significant increase in third-quarter revenue, driven by the Celgene acquisition. The company's GAAP EPS was $0.82, and non-GAAP EPS was $1.63. They are also planning to acquire MyoKardia to strengthen cardiovascular franchise.

Bristol Myers Squibb reported strong product sales and robust operating performance in the second quarter of 2020, driven by the Celgene acquisition. Total revenues reached $10.1 billion, a 61% increase. The company reported a GAAP loss per share of $0.04 and a non-GAAP EPS of $1.63. They updated 2020 non-GAAP EPS guidance range from $6.00-$6.20 to $6.10-$6.25.

Bristol Myers Squibb reported first quarter revenues of $10.8 billion, an increase of 82% on a reported basis and non-GAAP EPS of $1.72. The increase was driven primarily by the impact of the Celgene Acquisition. The quarter benefitted by approximately $500 million due to COVID-19 related buying patterns.

Bristol-Myers Squibb reported a transformative year in 2019, marked by the acquisition of Celgene, strong operational and financial performance, and advancements in science for patients.